You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 39 No. 9, September 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Brain Glucocerebrosidase in Gaucher's Disease

Lydia B. Daniels; Patrick J. Coyle, MS; Robert H. Glew, PhD; Norman S. Radin, PhD; Rosalind S. Labow, PhD

Arch Neurol. 1982;39(9):550-556.


Abstract

• Using glucocerebroside labeled with carbon 14 as the substrate, we determined that homogenates of brain tissue from both neuropathic and nonneuropathic cases of Gaucher's disease were profoundly deficient (more than 85%) in glucocerebrosidase activity. The β-glucosidase activity, as measured with 4-methylumbelliferyl-β-D-glucopyranoside as the substrate, in the homogenates of brain from four cases of Gaucher's disease was less sensitive to inhibition by conduritol B epoxide (CBE) when compared with normal brain β-glucosidase. However, when homogenates were assayed with radiolabeled glucocerebroside as the substrate, no differential sensitivity toward CBE was indicated, suggesting the presence of an additional, CBE-insensitive, β-glucosidase in brain tissue. Residual glucocerebrosidase activity partially purified from the brain of an adult with type 1 Gaucher's disease was activated threefold by gluconoyl hydrazine, whereas the same enzyme from control brain was unaffected, and eight times less sensitive to gluconolactone inhibition.



Author Affiliations

From the Department of Biochemistry, University of Pittsburgh School of Medicine (Ms Daniels, Mr Coyle, and Dr Glew); Mental Health Research Institute (Department of Psychiatry) and Department of Biological Chemistry, University of Michigan, Ann Arbor (Dr Radin); and National Research Council, Division of Biological Sciences, Ottawa (Dr Labow).


Footnotes

Accepted for publication Oct 1, 1981.

Reprint requests to Department of Biochemistry, University of Pittsburgh School of Medicine, 538 Scaife Hall, DeSoto Street, Pittsburgh, PA 15261 (Dr Glew).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Viable Mouse Models of Acid {beta}-Glucosidase Deficiency: The Defect in Gaucher Disease
Xu et al.
Am. J. Pathol. 2003;163:2093-2101.
ABSTRACT | FULL TEXT  

The Brain in Gaucher's Disease
Wenger
Arch Neurol 1984;41:251-252.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.